Trial · NCT03239145
Participant flow25
How many started, completed or left each group, period by period.
1 to 20 of 25
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 4 | |
| Overall Study | STARTED | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 3 | |
| Overall Study | STARTED | [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 39 | |
| Overall Study | STARTED | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 12 | |
| Overall Study | STARTED | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 4 | |
| Overall Study | Treated | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 3 | |
| Overall Study | Treated | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 3 | |
| Overall Study | Treated | [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 37 | |
| Overall Study | Treated | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 11 | |
| Overall Study | Treated | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 4 | |
| Overall Study | Outcome Analytic Cohort | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 | |
| Overall Study | Outcome Analytic Cohort | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 3 | |
| Overall Study | Outcome Analytic Cohort | [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 37 | |
| Overall Study | Outcome Analytic Cohort | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 11 | |
| Overall Study | Outcome Analytic Cohort | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 4 | |
| Overall Study | COMPLETED | [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 | |
| Overall Study | COMPLETED | [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 1 | |
| Overall Study | COMPLETED | [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal) | 1 | |
| Overall Study | COMPLETED | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian) | 0 | |
| Overall Study | COMPLETED | Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03239145/flow